TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 11/09/20

TFF Pharmaceuticals, Inc. (TFFP) Q3 2020 Earnings Conference Call November 5, 2020 16:30 ET Company Participants Paul Sagan - Investor Relations Glenn Mattes - President and Chief Executive Officer Kirk Coleman - Chief Financial Officer Dale Christensen - Director, Clinical Development Chris ...

TFF Pharmaceuticals (TFFP): Q3 GAAP EPS of -$0.24 misses by $0.05.Cash and cash equivalents of $41.6M.Press Release For further details see: TFF Pharmaceuticals EPS misses by $0.05

Signs Letter of Intent with Felix Biotechnology to license Thin Film Freezing technology for their bacteriophage products for lung inhalation Signs worldwide co-development agreement with Augmenta Bioworks for monoclonal antibody therapeutics Reports positive preclinic...

Felix Biotechnology would obtain worldwide license for Thin Film Freezing technology to develop a novel, bacteriophage-based biotherapeutic Proposed terms provide for upfront payments, clinical development milestone and commercial milestone payments to TFF Pharmaceuticals of u...

TFF Pharmaceuticals ([[TFFP]] +6.0%) and Augmenta Bioworks have entered into a development and collaboration agreement to develop products incorporating latter’s human-derived monoclonal antibodies ((mAbs)) for potential COVID-19 therapeutics.The products will be developed utilizing TF...

Companies to collaborate in first-of-its-kind uses of Thin Film Freezing technology applied to monoclonal antibodies TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthrou...

Company to hold conference call and webcast at 4:30 PM EDT TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platfo...

TFF Pharmaceuticals ([[TFFP]] +4.8%) has announce positive preclinical immunogenicity and efficacy data from thin film freezing formulated UGA universal Influenza hemagglutinin ((HA)) recombinant vaccines. The vaccine is under development in collaboration (announced in April this year) w...

TFF possess the rights to a game-changing drug formulation technology. They have a cost-efficient, fast route to market for their improved drugs. Management are forging partnerships with large companies to finance development. This is an under-followed, under-valued small cap ...

Company’s Thin Film Freezing dry powder was equivalent to the liquid universal influenza formulated vaccine in preclinical immunogenicity and efficacy testing TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing an...